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Abstract
Background
Antiretroviral therapy (ART) regimens containing efavirenz (EFV) are recommended as
part of universal ART for pregnant and breastfeeding women. EFV may have appreciable
side effects (SE), and ART adherence in pregnancy is a major concern, but little is known
about ART SE and associations with adherence in pregnancy.
Methods
We investigated the distribution of patient-reported SE (based on Division of AIDS catego-
ries) and the association of SE with missed ART doses in a cohort of 517 women starting
EFV+3TC/FTC+TDF during pregnancy. In analysis, SE were considered in terms of their
overall frequency, by systems category, and by latent classes.
Results
Overall 97% of women reported experiencing at least one SE after ART initiation, with 48%
experiencing more than five SE. Gastrointestinal, central nervous system, systemic and
skin SE were reported by 81%, 85%, 79% and 31% of women, respectively, with consider-
able overlap across groups. At least one missed dose was reported by 32% of women. In
multivariable models, ART non-adherence was associated with systemic SE compared to
other systems categories, and measures of the overall burden of SE experienced were
most strongly associated with missed ART doses.
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Conclusion
These data demonstrate very high levels of SE in pregnant women initiating EFV-based
ART and a strong association between SE burden and ART adherence. ART regimens with
reduced SE profiles may enhance adherence, and as countries expand universal ART for
all adult patients, counseling must include preparation for ART SE.
Background
With the recent adoption of Option B+ for prevention to mother-to-child HIV transmission
(PMTCT) there have been rapid increases globally in the use of antiretroviral therapy (ART)
by HIV-infected pregnant and breastfeedingwomen.[1] Following initiation of ART, successful
treatment implementation and continued adherence to lifelong therapy is a widespread con-
cern, emerging as a particular issue for women initiating ART during the perinatal period.[2,3]
In turn, understanding adherence under Option B+ and the determinants of non-adherence, is
a major priority both for individual and program level PMTCT outcomes.
Medication side effects (SE) are commonly thought to influence treatment adherence.[4–6]
Efavirenz (EFV)-containing ART regimens are currently recommended by theWHO as first
line treatment. They are widely used in resource-limited settings and are generally considered
to be better tolerated than previous NNRTI regimens.[7–10]However, specific SE associated
with EFV are well known, particularly neuropsychiatric SE such as dizziness and vivid dreams.
[11,12] In general, SE from current first line therapy are thought to be relatively short lived and
improve as patients continue on ART. However, these early SE may disrupt initial implementa-
tion of the regimen, and there is some evidence that early treatment adherence is important to
set the course of long term adherence and treatment success.[13] Early adherence, particularly
during pregnancy, is required to ensure rapid viral suppression, reduced transmission risk and
improved maternal health outcomes.
Experience of SE has been associated with non-adherence and discontinuation of ART in
general adult populations using various regimens.[12,14–19]However, few studies focus spe-
cifically on EFV-containing regimens and treatment adherence. One study in a small general
adult cohort in South Africa, the majority on EFV-based regimens, found that experience of
symptoms was associated with lower self-reported adherence scores.[17] Fear and experiences
of SE have beenmooted as threats to ART adherence and continued ART use both in general
adult patients as well as in pregnant and postpartumwomen.[3,15,20–25]
The role of SE in ART adherence warrants special attention in pregnant and postpartum
women. To date evaluations of SE in pregnant populations have beenmostly limited to clini-
cian-reported adverse events, primarily in trial settings.[26–29] Yet patients’ experiences of SE
may differ from clinician-reported adverse events.[7,18,30]While data on SE under Option B
+ are few, country-level data show high rates of early loss to follow-up under Option B+, par-
ticularly among women with higher baseline CD4 cell counts, which may be attributable in
part to ART SE.[31,32] The experience and tolerance of ART SE in relatively healthy individu-
als, commonly the case in pregnant women initiating ART under Option B+, may differ from
that of individuals with more advanced HIV disease.[30,33–35]Also, in the context of preg-
nancy, ART initiation is frequently fast-tracked to maximize the chances of reaching viral sup-
pression by delivery. There may be limited time to counsel patients on common SE and their
management, and lack of preparation for SE has been suggested as a risk factor for poor adher-
ence in the context of Option B+.[23]
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Despite the importance of these issues, little is known about experience of SE and the rela-
tionship with adherence after ART initiation in pregnancy, particularlywith first line EFV-con-
taining regimens in the context of Option B+.We examined the occurrence and patterns of SE
during pregnancy among women initiating EFV-based ART, and investigated the relationship
between reported SE and reportedmissed ART doses.
Methods
Population
This analysis draws on data from a large multi-phase trial evaluating strategies for delivering
HIV care and treatment services during pregnancy and the postpartum period (The
MCH-ART study, https://clinicaltrials.gov/ct2/show/NCT01933477).[36] The study took place
in a large public sector antenatal clinic (ANC) in Gugulethu, Cape Town, South Africa. This
setting is characterized by high levels of poverty and HIV with a local antenatal HIV seropreva-
lence of 33%.[37] Local public sector health services have provided free ART services since
2004 and from 2012 ART was delivered within the ANC. From July 2013, all HIV-infected
pregnant women were eligible to start lifelong ART regardless of CD4 cell count or clinical
stage (Option B+).[38]
ConsecutiveHIV-infected, ART-eligible pregnant women 18 years and older making their
first ANC visit during the current pregnancy were enrolled into the MCH-ART study between
April 2013 and June 2014. Overall, 526 women were enrolled under Option B+ which started
on 1 July 2013. Women started a first line regimen of EFV (600mg), emtricitabine (FTC)/ lami-
vudine (3TC) (300mg) and tenofovir (TDF) (300mg) (EFV+FTC/3TC+TDF), provided as a
fixed dose combination. ART initiation and follow-up was conducted by nurse-midwives
within the ANC. ART was usually initiated on the day of the first antenatal visit or within two
weeks, with routine follow-up visits occurringmonthly for the first four months on treatment
and one to two monthly thereafter. ART counselling was provided by trained counsellors
before initiation and at each follow-up visit.
The cohort was followed through study assessments conducted separately from routine
care. Participants completed an interviewer-administered questionnaire at the time of enrol-
ment, up to twice more during pregnancy, and once immediately after delivery. Each study
assessment included structured questionnaires on ART use, and at the first postpartum study
visit self-reported SE experienced since ART initiation were assessed. This study was conducted
in accordance with the ethical standards of the 1964 Helsinki declaration and its later amend-
ments, and was approved and conducted in accordance with the standards of the Human
Research Ethics Committee of the University of Cape Town and the Columbia University
Medical Centre Institutional ReviewBoard. All participants provided written informed
consent.
Measures
A structured questionnaire based on Division of AIDS (DAIDS) Tables for grading adverse
events[39] was used to collect information on SE experienced, including gastrointestinal (GIT)
(nausea/vomiting, appetite change, diarrhea, other GIT), central nervous system (CNS) (head-
ache, dizziness, unusual dreaming, other CNS), skin (rash, other skin), systemic (fatigue, fever/
sweats, non-specific pain, other systemic) SE. The collected information was codifiedusing a
set of 14 binary variables for the reporting of each SE from ART initiation through to the first
postpartum study visit.
Missed doses in the preceding 30 days were reported at each visit. The average number of
missed ART doses was calculated by summing the reportedmissed doses across all study visits
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betweenART start and the first postpartum visit. The sum of missed doses was divided by the
sum of the reference period (the maximum number of visits on ART completed was three,
resulting in a maximum reference period of 90 days) and multiplied by 30 to obtain the average
number of missed doses in a 30-day period. This was analyzed as both a continuous and binary
variable (any vs. no missed doses). A secondary outcome of a reported period of no treatment
for 30 days or more at the time of the last assessment was also evaluated.
Analysis
This secondary analysis of data from the MCH-ART study excluded women enrolled under
the Option A policy as well as women who did not have data available on side effects in preg-
nancy (n = 9). Women were included regardless of mode of delivery. Data were analyzed using
Stata Version 12.0 (Stata Corporation, College Station, Texas, USA) and MPlus Version 7.3
(Muthén &Muthén, Los Angeles, CA). Variables were describedusing medians (with inter-
quartile ranges, IQR) and proportions with (95% confidence intervals, CI). We used rank-sum
and chi-square (replaced in the case of sparse data by Fisher’s exact) tests to examine differ-
ences in central tendencies and proportions, respectively. Three different constructs were used
to examine the patterns of SE reported by participants and the associations with missed ART
doses:
a. Systems categories: A classification based on Division of AIDS (DAIDS)[39] categories was
used to divide reported SE into groups of gastrointestinal (GIT), central nervous system
(CNS), skin and systemic SE. Assignment to these categories was not mutually exclusive.
b. Cumulative number of SE: Subjects were grouped according to the number of different types
of SE experienced since ART initiation (from no SE reported to up to 14 different SE).
c. Latent SE class: Latent Class Analysis (LCA) was used to classify individuals into mutually
exclusive groups (latent classes) characterized by different pattern of SE, allowing for pat-
terns that may not be solely systems-based (as assumed in [a] above). LCA, a statistical
method for inferring unmeasured class membership using a set of measured variables as
imperfect class indicators, has been used to identify underlying patterns of signs and symp-
toms in other contexts.[40–43] Here the binary variables representing presence/absence of
different SE since ART initiation were used as indicators, and the optimal number of latent
classes was determined by comparing the fit of models with different number of classes
according to statistical information criteria together with the results of the bootstrap likeli-
hood ratio test.[44] Individuals were assigned to each class according to the maximum pos-
terior probability. The LCA process is described in S1 and S2 Tables.
Multiple logistic regression was used to investigate adjusted associations between reported
SE (according to the three different classifications described above) and reportedmissed ART
doses. Covariates with associations at p0.10 in the bivariate models were included in the mul-
tivariable models.When analyzing predictors of latent class membership, the probability of
misclassification of individuals was taken into account in the estimation, using the three-step
approach describedby Asparouhov and Muthén.[45]
Results
Overall, 517 women who initiated ART in pregnancy under Option B+ were included in this
analysis (Table 1). The median age was 28 years, 74% of women had not completed secondary
school and 63% were unemployed. At ART initiation, the median CD4 cell count was 361
cells/μL (IQR 244–539 cells/μL) and the median gestational age was 21 weeks (IQR 16–27
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weeks). HIV diagnosis occurredduring the current pregnancy for 55% of women and 28% had
used some form of antiretroviral previously (predominantly short-course PMTCT regimens).
All women received folic acid, calcium carbonate and iron supplements during antenatal care,
and 6 women were treated for tuberculosis during pregnancy. At the time of the SE assessment
postpartum (median, 7 days after delivery) the median duration of ART use was 19 weeks
(IQR 12–23 weeks).
Prevalence of side effects
Overall, 97% of women (n = 502) reported experiencing at least one SE on ART during preg-
nancy. Only median duration on ART differed betweenwomen who did and did not report SE
Table 1. Demographic characteristics of 517 women initiating ART during pregnancy included in the study, by reported side effects (SE). All cells
are N (%) unless otherwise specified.
All women Any SE >5 SE 1–5 SE No SE p-value (any vs none)
Number of women 517 502(97) 250(48) 252 (49) 15(3) -
Median age (IQR) 28(24–32) 28(25–32) 28(24–32) 28(25–32) 33(23–34) 0.364
Socioeconomic status
lowest 197(38) 190(38) 103(41) 87(35) 7(47) 0.758
medium 152(29) 149(30) 68(27) 81(32) 3(20)
highest 168(33) 163(32) 79(32) 84(33) 5(33)
Education level
Finished high school 134(26) 130(26) 59(24) 71(28) 4(27) 1.000
Did not finish high school 383(74) 372(74) 191(76) 181(72) 11(73)
Employment status
Employed 193(37) 187(37) 91(36) 96(38) 6(40) 0.794
Not employed 324(63) 315(63) 159(64) 156(62) 9(60)
Relationship status
Married/cohabiting 198(38) 194(39) 88(35) 106(42) 4(27) 0.427
Not married/cohabiting 319(62) 308(61) 164(65) 144(58) 11(73)
Median gravidity (IQR) 2(2–3) 2(2–3) 2(2–3) 2(2–3) 3(2–3) 0.183
Primigravida 93(18) 91(18) 50(20) 41(16) 2(13) 1.000
Mulitgravida 424(82) 411(82) 200(80) 211(84) 13(87)
Timing of HIV diagnosis
In the current pregnancy 286(55) 278(55) 135(54) 143(57) 8(53) 1.000
Prior to this pregnancy 231(45) 224(45) 115(46) 109(43) 7(47)
ARV history
ARV naïve 374(72) 365(73) 186(74) 179(71) 9(60) 0.386
Previous PMTCT 126(24) 120(24) 53(21) 67(27) 6(40)
Previous ART 17(3) 17(3) 11(4) 6(2) 0(0)
Median CD4 cell count at ART initiation (IQR) § 361(244–
539)
359(242–
536)
337(225–
507)
390(271–
553)
502(294–
635)
0.104
CD4<200 85(17) 85(18) 52(21) 33(14) 0(0) 0.200
CD4 200–349 150(30) 145(30) 76(31) 69(29) 5(33)
CD4350 265(53) 255(53) 115(47) 140(58) 10(67)
Median gestation(weeks) at ART initiation
(IQR)
21(16–27) 21(16–27) 20(15–25) 22(17–29) 23(13–21) 0.360
Median weeks on ART (IQR) 19(12–23) 19(12–23) 19(15–24) 17(10–23) 9(4–21) 0.012
§17missing CD4 count
doi:10.1371/journal.pone.0163079.t001
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(19 and 9 weeks, respectively; p = 0.012) (Table 1). The median number of different SE experi-
enced was five (IQR 3–7; max 12) and 91% of women reported two or more different SE. GIT,
CNS, systemic and skin SE were reported by 81%, 85%, 79% and 31% of women, respectively.
There was considerable overlap in SE reporting (Fig 1) with 22% of women (n = 112)
experiencing at least one SE from all four categories, and 40% (n = 208) reportingGIT, CNS
and systemic side effects. The distributions of each SE construct by socio-demographic sub-
groups are displayed in S3 Table.
Latent side effect classes
Four distinct patterns of SE identified using LCA are shown in Fig 2 and described in Table 2.
One group of women, comprising 26% of the cohort, reported experiencingmost of the
assessed SE (here referred to as Class 1). A second group (Class 2, 17% of the cohort) frequently
reported experiencing systemic SE but reported experiencingCNS, GIT and skin SE less com-
monly. Class 3 (30% of women) reported experiencing all types of SE less commonly (including
systemic SE), while a fourth class (27% of women) reported experiencing few SE.
In a multinomial logistic regression adjusted for age and number of weeks on ART, educa-
tion, CD4 count and gestation at ART initiation were significantly associated with class mem-
bership (S4 Table). Women with lower CD4 counts at ART initiation were more likely to
belong to Class 1 than other classes. Increased education predictedmembership to Class 3,
experiencingmoderate levels of all SE, compared to Class 1, experiencingmost or all types of
Fig 1. Venn diagram of number of women reporting each side effect by system category.
doi:10.1371/journal.pone.0163079.g001
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SE. In addition, starting ART earlier in pregnancy was associated with higher probability of
belonging to latent classes characterized by higher levels of SE (Classes 1 and 2).
Side effects and ART adherence
At least one missed ART dose during pregnancy was reported by 32% of women (n = 166).
Among these women, 87% (n = 145) reported between one and three missed doses, and the
remaining 13% (n = 21) reported four or more missed doses, per 30 days on ART, respectively.
(Table 2) Women who experienced any SE were significantlymore likely to report any missed
ART dose compared to those who reported no SE (100% versus 96%, p = 0.003).Women with
any missed dose reported a marginally higher number of individual SE compared to women
reporting no missed doses (median 5 versus 6 reported SE, p<0.001).
Fig 3 shows the proportions of women reporting individual SE grouped by reporting any
versus no missed doses. For all systems SE groups, the proportion of women reporting SE was
higher among those whomissed any dose compared to those who reported no missed doses.
Fig 2. Proportion of women reporting each side effect by latent side effect (SE) classes; systems-based
SE categories are shown in green (systemic SE), yellow (skin SE), red (central nervous system SE) and
blue (gastrointestinal SE).
doi:10.1371/journal.pone.0163079.g002
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Table 2. Reported side effects among 517 women following ART initiation during pregnancy in Cape Town, South Africa. All cells are N (%) unless
otherwise specified.
All women Missed doses in 30 days (on average) Discontinued ART p-value (any versus no missed
dose)None 1–3 4 or
more
Any
missed
on ART Stopped
ART
Number of women 517 351 145 21 166 511 6
Any side effect reported 502(97) 336
(96)
145
(100)
21(100) 166(100) 496
(97)
6(100) 0.003
Median number of reported SE
(IQR)
5(3–7) 5(2–7) 6(4–8) 8(5–9) 6(4–8) 5(3–7) 8(7–9) <0.001
No reported SE 15(3) 15(4) 0(0) 0(0) 0(0) 15(3) 0 <0.001
Only 1 reported SE 32(6) 28(8) 3(2) 1(5) 4(2) 31(6) 1(17)
More than 1 reported SE 470(91) 308
(88)
142(98) 20(95) 162(98) 465
(91)
5(83)
Any GIT SE 417(81) 269
(77)
131(90) 17(81) 148(89) 412
(81)
5(83) 0.001
Nausea or vomiting 337(65) 215
(61)
107(74) 15(71) 122(73) 332
(65)
5(83) 0.006
Diarrhea 204(39) 122
(35)
73(50) 9(43) 82(49) 202
(40)
2(33) 0.001
Appetite change 247(48) 147
(42)
89(61) 11(52) 100(60) 244
(48)
3(50) <0.001
Other GIT 11(2) 6(2) 4(3) 1(5) 5(3) 11(2) 0 0.272
Any CNS SE 437(85) 289
(82)
128(88) 20(95) 148(89) 431
(84)
6(100) 0.045
Dizziness 327(63) 208
(59)
101(70) 18(86) 119(72) 321
(63)
6(100) 0.006
Unusual dreaming 250(48) 160
(46)
75(52) 15(71) 90(54) 246
(48)
4(67) 0.067
Headache 278(54) 182
(52)
82(57) 14(67) 96(58) 273
(53)
5(83) 0.203
All other CNS SE 20(4) 10(3) 9(6) 1(5) 10(6) 19(4) 1(17) 0.080
Any skin SE 161(31) 102
(29)
48(33) 11(52) 59(36) 158
(31)
3(50) 0.137
Rash 154(30) 95(27) 48(33) 11(52) 59(36) 151
(30)
3(50) 0.049
All other skin SE 11(2) 8(2) 2(1) 1(5) 3(2) 11(2) 0 0.728
Any systemic SE 406(79) 256
(73)
131(90) 19(91) 150(90) 401
(78)
5(83) <0.001
Fever or sweats 303(59) 191
(54)
96(66) 16(76) 112(67) 299
(59)
4(67) 0.005
Other nonspecific pain 215(42) 126
(36)
75(52) 14(67) 89(54) 210
(41)
5(83) <0.001
Fatigue 310(60) 190
(54)
104(72) 16(76) 120(72) 305
(60)
5(83) <0.001
All other systemic SE 48(9) 30(9) 14(10) 4(19) 18(11) 48(9) 0 0.401
Class 1 (high SE) 133(26) 74(21) 31(28) 28(51) 59(36) 130
(25)
3(50) <0.001
Class 2 (moderate SE, high
systemic)
89(17) 55(16) 26(23) 8(15) 34(20) 87(17) 2(33)
Class 3 (moderate SE) 156(30) 105
(30)
37(33) 14(25) 51(31) 156
(31)
0(0)
Class 4 (low SE) 139(27) 117
(33)
17(15) 5(9) 22(13) 138
(27)
1(17)
doi:10.1371/journal.pone.0163079.t002
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These differences were statistically significant for all GIT, systemic and skin SE, except for the
“other” categories which were reported at very low frequencies. Of the CNS SE, only dizziness
was associated with reporting any missed ART doses. In the analysis of SE as latent classes,
missed doses were reportedmore frequently in classes where SE reporting was more common:
36%, 21%, 31% and 13% of women who reported any missed ART during pregnancy were in
Classes 1, 2, 3 and 4, respectively (p<0.001).(Table 2)
The associations between each SE construct (including frequency of SE, systems classifica-
tion and latent classes) and missed ART doses were considered separately in multivariable
logistic regression models adjusted for participant age, marital status, parity and time on ART.
In all models, SE were consistently associated with missed ART doses (S4 Table). CD4 cell
count, although associated with reporting SE, was not associated with missed doses and did not
appear to confound the association between reported SE and missed ART doses. Higher num-
bers of different reported SE were associated with increasing odds of a missed dose (OR 1.20,
CI 1.12–1.29, for each additional type of SE reported). Using systems SE categories, having any
Fig 3. Proportions of women reporting each side effect with 95% confidence intervals, by any or no missed doses reported.
doi:10.1371/journal.pone.0163079.g003
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GIT or any systemic SE was associated with increased odds of reportingmissed doses (OR 1.78
[CI 1.00–3.17] and OR 2.65 [CI 1.46–4.81], respectively). However CNS and skin SE were not
associated with self-reported adherence. Compared to women in Class 1, women in Class 4
(with the lowest SE profile) had significantly lower odds of reporting any missed dose (OR
0.25, CI 0.14–0.45). These associations did not change appreciably whenmode of delivery was
included in the final model.
Six women (1%) reportedmissing 30 or more ART doses and the time off ART at assess-
ment ranged from 43 to 156 days. The reasons reported for missing more than 30 days of ART
are shown in S5 Table. Five out of six women were in Classes 1 or 2 where the experience of SE
was highest, and four of the six women cited SE among the reasons for stopping to take their
treatment.
Discussion
Our study is the first to document very high levels of SE experiencedby women initiating efa-
virenz-basedART during pregnancy in sub-Saharan Africa and an association with self-
reportedmissed ART doses.Missed doses were reported frequently. However, we found no
persistent associations between specific SE and missed doses; instead, the strongest associations
with missed doses involved measures of the overall burden of SE experiencedby women. This
finding adds an important new perspective to ART adherence in pregnancy under Option B+.
Overall, 97% of women reported at least one SE and the vast majority of women reported
multiple SE. While there are few data on ART SE reporting in pregnancy and methods of mea-
surement vary, these levels appear substantially higher than in other studies of first line, EFV-
containing regimens in non-pregnant adults.[7,17,46] As in other analyses of medication SE in
pregnant women, it is not clear if the SE reported here were related to the antiretrovirals, rou-
tine supplements given in pregnancy (iron, folate and calcium), symptoms of pregnancy, or
symptoms of HIV disease. Unfortunately we did not collect data on additional supplements
however, use of over the counter supplements in this setting is not common. Concurrent tuber-
culosismedicationmay also impact reported side effects however less than 1% of this cohort
had a tuberculosis episode during pregnancy. GIT and systemic SE may be related to physio-
logic changes of pregnancy, many of which typically occur early in pregnancy. The median ges-
tation at ART start in this cohort was 21 weeks, meaning most women were well into the
second trimester when they initiated ART. The finding that women with lower CD4 cell counts
appeared to experiencemore diverse SE in both the absolute count and latent class analysis
suggests that some of this reportingmay be linked to HIV disease rather than ART use directly.
There are concerns that healthier individuals starting ART may have more adherence prob-
lems. However, our findings show that individuals with lower CD4 cell counts are likely to
experiencemore SE and therefore may also be at risk for poor adherence. These findingsmay
have important implications for universal ART initiation in pregnancy as well as for adult “test
and treat” approaches. Appropriate counselling and support for SE management is required
both to prepare healthy individuals for the effects of ART, as well as to prepare the individuals
with more advanced disease for the effects of their HIV and ART.
In general, EFV SE are thought to be relatively short-lived and improve over time. How-
ever, early SE on ART have not been well documented in the literature. Our findings suggest
that women who booked for ANC later, and therefore had a longer duration on ART, report
more SE than women with less time on ART. Further research on the timing and severity of
ART SE during pregnancy and in non-pregnant women and healthy adults will be valuable
to better understand these SE profiles and provide appropriate support in the early time on
treatment.
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Regardless of the underlying cause, all three constructs of reported SE (number of different
SE reported, systems-based SE categories, and latent SE classes) were associated with reported
missed ART doses. There was more imprecision around some associations between any SE or
specific SE and missed doses observed in the logistic regression estimates in S4 Table, likely
due to the very high proportions of women reporting SE in this cohort. In all three of the SE
constructs used, effect sizes were relatively small and no specific SE appeared to be driving
missed doses in any of the analyses. Although this may in part be due to inability to detect
small differences with relatively homogenous reports of SE overall, this finding suggests that
non-adherencemay not be related to any one specific type or cluster of SE (for example nausea
or dizziness), but rather to the overall SE burden.
This finding has several possible interpretations. The experience of multiple SE may present
a cumulative burden of physical symptoms, any one of which may not contribute to non-
adherence in isolation. There is evidence that the experience of SE is related to plasma antire-
troviral levels, including EFV, which in turn may be moderated by genetic polymorphisms
influencing drugmetabolism.[47] The polymorphism resulting in increased plasma EFV levels
has been found to be relatively common in patients of African descent, and high EFV concen-
trations have been associated with experiencing EFV related SE.[47, 48] In addition to this
physiologic explanation, it is important to note that the reporting of larger numbers of SE may
bemore common in individuals with specific personality traits, such as neuroticism.[49] In
this context it is plausible that mental health concerns may contribute to SE reporting as well
as to non-adherence. These and other possible interpretations warrant additional attention.
This is the first report of SE experiencedby pregnant women starting ART under Option B
+ in South Africa. The data provide novel insights but are subject to important limitations. All
women in this analysis were on a regimen of EFV+FTC/3TC+TDF, the regimen initiated by
the majority of HIV-infected pregnant women under current global policy. However, we were
unable to examine how this regimen compares to others with respect to reported SE and adher-
ence. As individual antiretroviral agents have different SE profiles, the possibility that different
ART regimens may have less SE and contribute to better adherence in pregnancy is a pertinent
consideration. The prevalence of reported CNS SE, a specific concern in EFV-containing regi-
mens, was very high and limited our ability to examine associations with non-adherence in this
analysis.[11] More generally, all SE and adherence data was based on patient self-report, and
social desirability may have led to misreports of ART adherence and/or reported SE, though
we note the relatively high levels of missed dose reporting in this sample.
Despite these limitations, these findings have important implications for health services
providing ART to pregnant women. Experiences of SE and fear of SE have been reported as
barriers to adherence to ART in pregnancy.[3,20,22,23] The high level of reported SE and the
association with missed doses found in this cohort supports previous calls for specific counsel-
ling on ART SE.[6,50] Antenatal ART initiation is often rapid to ensure maximum time on
ART prior to delivery. Time for pre-ART counsellingmay be limited, however counselling to
address possible ART SE, as well as pregnancy symptoms which may be perceived as ART
related, should be a focus both at treatment initiation as well as subsequent follow up visits.
More generally, the high burden of SE experienced in this cohort using EFV+FTC/3TC+TDF
points to the ongoing need both to understand the causes of SE in context of pregnancy, and to
identify new agents that minimize experience of SE.
In summary, these novel data are important in demonstrating a high level of SE experienced
in this population of pregnant women initiating a first line EFV-containing regimen under
Option B+. The overall burden of SE experience, rather than specific SE, appears persistently
associated with self-reportedmissed ART doses. Although the reported SE may not be directly
related to antiretroviral regimen, these data highlight that patient reported SE in the early time
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on ART may impact treatment adherence and there is a clear need to include counselling on
expectedART SE at ART initiation and follow-up visits. In this analysis we did not find an
association betweenCD4 cell count and missed ART doses which is reassuring for universal
ART policies. As many countries move towards a “test and treat” approach, providing ART for
all HIV-infected adults, the lessons we have learned from rapid universal ART initiation in
pregnancy should be carefully considered.Managing experience and perception of ART SE
may play an important role in optimizing adherence behavior during this early treatment
period,which could in turn improve long term treatment outcomes.
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